The Patent Finder

Barr Laboratories, Inc.

Also on record
Records under this name other than the patents Barr Laboratories, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.

Back to Barr Laboratories, Inc.

PatentTitleStatus Expires Confidence
US 10,406,154Transdermal Dosage Form
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 10,010,543Transdermal Dosage Form
Formerly held
Lapsed on the fee record
Ended Jul 3, 2026 · Medium confidence
Lapsed on the fee recordEnded Jul 3, 2026Medium confidence
US 7,320,969Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Formerly held
Term ended
Term ended Jan 30, 2024 · From the USPTO record
Term endedTerm ended Jan 30, 2024From the USPTO record
US 7,858,605Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Formerly held
Lapsed on the fee record
Ended Dec 28, 2022 · From the USPTO record
Lapsed on the fee recordEnded Dec 28, 2022From the USPTO record
US 8,680,084Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Formerly held
Lapsed on the fee record
Ended Mar 25, 2022 · From the USPTO record
Lapsed on the fee recordEnded Mar 25, 2022From the USPTO record
US 7,615,545Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Formerly held
Lapsed on the fee record
Ended Nov 10, 2021 · From the USPTO record
Lapsed on the fee recordEnded Nov 10, 2021From the USPTO record
US 6,660,726Estrogenic compounds, pharmaceutical compositions thereof, and methods of using same
Formerly held
Term ended
Term ended Mar 8, 2021 · From the USPTO record
Term endedTerm ended Mar 8, 2021From the USPTO record
US 6,844,334(3) and (6) substitued estrogenic compounds
Formerly held
Term ended
Term ended Mar 8, 2021 · From the USPTO record
Term endedTerm ended Mar 8, 2021From the USPTO record
US 8,338,396Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
Formerly held
Lapsed on the fee record
Ended Dec 25, 2020 · From the USPTO record
Lapsed on the fee recordEnded Dec 25, 2020From the USPTO record
US 7,459,445Estrogenic compounds and topical pharmaceutical formulations of the same
Formerly held
Lapsed on the fee record
Ended Dec 2, 2020 · From the USPTO record
Lapsed on the fee recordEnded Dec 2, 2020From the USPTO record
10 of 35 patents shown.
Pro members see all 35.
Pro members: see all 35 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited